Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Lignende værker

• Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
  af: Hughes, Timothy, et al.
  Udgivet: (2009)
• Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis
  af: Snead, Jennifer L., et al.
  Udgivet: (2009)
• Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
  af: Jabbour, Elias, et al.
  Udgivet: (2012)
• BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
  af: Hughes, T P, et al.
  Udgivet: (2015)
• Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
  af: Stein, Andrew M, et al.
  Udgivet: (2013)